Direct intratumoral injection harnesses CPMV's intrinsic immune-stimulating properties to reprogram "cold" tumors and induce a systemic, anti-tumor adaptive immune response.
Cowpea Mosaic Virus (CPMV) based Nanoparticle for Targeted Drug Delivery
Are you currently facing long drug development cycles, difficulty in achieving precise targeting, or challenges in effective immune modulation? Our Creative Biolabs VLP Development service helps you accelerate drug discovery and streamline clinical trial processes through advanced VLP engineering and translational oncology models. This highly sophisticated platform delivers high-quality, structurally precise nanoparticles for next-generation therapeutics.
Click Here to View more about our Services
Introduction of Cowpea mosaic virus (CPMV)-Based Nanoparticles
Creative Biolabs leverages the exceptional properties of the Cowpea mosaic virus (CPMV), a plant-derived nanoparticle, as a versatile platform to address both challenges simultaneously. CPMV is a highly stable, icosahedral virus-like particle (VLP) that is non-replicating in mammalian systems, positioning it as an inherently safe and potent nanoparticles and immune adjuvant.
What are CPMV-based NPs?
Creative Biolabs' VLP Development service focuses on engineering the CPMV capsid for high-value applications in medicine. The VLP platform is a specialized service that provides self-assembling, structurally precise protein cages for advanced biomedical applications. Unlike traditional synthetic carriers, CPMV's protein-based architecture offers unmatched uniformity and modifiable surfaces.
Application Scenarios
In Situ Cancer Immunotherapy
Targeted Drug and Gene Delivery
The CPMV surface is chemically functionalized to carry therapeutic payloads and display targeting ligands for precision delivery to diseased tissues.
Diagnostic Bioimaging
CPMVs are used as highly specific scaffolds for conjugating contrast agents, enabling non-invasive imaging and diagnosis.
Fig.1 Schematic diagram of the immunomodulatory impact of CPMV and calreticulin nanoparticles administered intratumorally in canine tumors.1
Why Choose Us?
CPMV-Based Nanoparticles offer advantages that significantly de-risk and accelerate therapeutic development:
Inherent Potency
CPMV acts as a potent Pathogen-Associated Molecular Pattern (PAMP), recognized by multiple Toll-Like Receptors, providing a powerful intrinsic adjuvant effect unmatched by many synthetic systems.
Structural Precision
The particle exhibits well-defined, atomic-resolution architecture, which enables reliable structure-guided design and modification.
High Stability
The robust icosahedral structure ensures stability during formulation, storage, and biological distribution in vivo.
Biocompatibility
Demonstrated minimal toxicity and high-dose tolerability in translational models, positioning it as a safe delivery vehicle.
Key Technologies
Creative Biolabs' technical mastery over CPMV centers on engineering its surface and interior with atomic precision to dictate its biological function, ensuring optimal performance for targeted therapeutics.
Discover How We Can Support - Arrange a Meeting!
Engineering Key Points
Utilize recombinant DNA technology to genetically insert peptide epitopes or small protein domains into the VLP's coat proteins. This allows for the precise, controlled display of antigens for vaccine development or affinity peptides for enhanced targeting.
The CPMV surface contains specific lysine and cysteine residues that can be chemically modified. Employ advanced "click" chemistry to attach targeting ligands or therapeutic payloads. This ensures the payload is attached reliably without compromising the VLP's structural integrity or immune-stimulating function.
Maximizing the activation of the NF-κB signaling pathway, which is central to upregulating pro-inflammatory cytokines, initiating the shift from immunosuppressive M2 macrophages to cytotoxic M1 phenotypes, and promoting dendritic cell maturation.
Cutting-Edge Technology
| CPMV Targeting Strategy | Biological Goal/Target Cell Type | Application Example |
|---|---|---|
| Folate Receptor Targeting | Cancer Cells (Epithelial tumors, Ovarian, Breast) | Targeted delivery of therapeutic payloads to tumors that over-express the folate receptor, minimizing systemic side effects. |
| Transferrin Receptor Targeting | Cancer Cells / CNS Targeting (Crossing the BBB) | High-efficiency payload delivery via receptor-mediated endocytosis for highly aggressive or difficult-to-treat tumors, including those behind the blood-brain barrier. |
| Innate Immune Activation | Antigen-Presenting Cells (Dendritic Cells, Macrophages) | In Situ Immunotherapy, transforming the tumor into a personalized vaccine, leading to TME reprogramming and cytotoxic T-cell infiltration. |
| Chemical Attachment Sites | Diverse Payloads (Small molecules, Toxins, Fluorescent Dyes) | Multivalent display of diagnostic probes or toxic agents for high-contrast bioimaging or targeted cell ablation. |
QC Method: Building Trust and Reliability
Creative Biolabs maintains the highest standards of quality control and validation for every VLP development project. Our core analytical methods confirm the purity, structural integrity, and biological activity of the final vector before delivery, providing clients with full confidence in their therapeutic candidate.
Structural and Physico-chemical Integrity
Confirm the physical characteristics of the VLP using TEM to verify icosahedral symmetry, Dynamic Light Scattering (DLS) to confirm monodisperse size distribution, and Fast Protein Liquid Chromatography to guarantee the absence of aggregates and free coat proteins.
Identity and Purity
SDS-PAGE is used to confirm the presence of the expected VLP coat protein subunits.
Functional Validation
For immunotherapeutic applications, employ Flow Cytometry on cellular models to validate the expected TME shift and the upregulation of key immune-related genes.
Key Benefits
Creative Biolabs' CPMV-Based Nanoparticles offer unique features that translate directly into accelerated R&D timelines and enhanced therapeutic outcomes for our clients:
Unmatched Scalability
Plant-based production method ensures a secure, high-yield, and low-cost supply chain capable of meeting the demands of large-scale clinical trials and eventual commercialization.
Potent Synergy with Standard-of-Care
CPMV's PAMP activity naturally complements the mechanism of action of many chemotherapeutics. This combination has demonstrated synergistic efficacy.
Atomic Precision in Targeting
The high-resolution structure allows for high-efficiency, multi-modal conjugation of targeting ligands and payloads via precise bioorthogonal click chemistry, leading to optimized target engagement and minimized off-target effects.
Tumor-Agnostic Efficacy
The mechanism of TME reprogramming is applicable across diverse tumor types, broadening the potential market and utility of the VLP platform.
Leverage Your Edge with Creative Biolabs - Request a Quote Today!
Products
| Products | Description | Inquiry |
|---|---|---|
| Targeted Polymer Products | Targeted polymers are engineered macromolecules that act as smart carriers for therapeutic agents, designed to improve the therapeutic index by enhancing drug concentration at target sites while reducing off-target effects. | |
| Lipid Nanoparticle Products | LNPs, as a leading non-viral vector platform for nucleic acid delivery, are precisely engineered self-assembling systems designed to protect and deliver therapeutic payloads |
Frequently Asked Questions
How does the CPMV VLP platform compare to traditional liposomal or polymeric nanoparticles?
CPMV offers two distinct advantages: uniformity and inherent bioactivity. Unlike synthetic carriers, the CPMV VLP is a highly uniform, monodisperse protein cage, ensuring unparalleled batch-to-batch consistency. Furthermore, its inherent PAMP status means it is not just a passive carrier; it actively stimulates the innate immune system, adding an essential therapeutic dimension often lacking in purely synthetic systems. To explore how this intrinsic immune activation can benefit your specific project.
Given that CPMV is a plant virus, what precautions are taken to ensure no mammalian cell infection occurs?
The CPMV VLP is non-infectious to mammalian cells. Its replication machinery is specific to Vigna unguiculata (cowpea) plants. The stringent purification and quality control methods used by Creative Biolabs, guarantee that the final product is a non-replicating, structurally intact protein cage, ensuring patient safety.
Is the therapeutic effect of CPMV localized to the injected tumor, or can it treat metastases?
The beauty of our CPMV immunotherapy platform is that it leverages the localized injection to drive a systemic anti-tumor response. The local injection causes TME reprogramming and antigen presentation, leading to the priming of tumor-specific T cells. These activated T cells then circulate throughout the body, and treat untreated, distant metastases. This is the key to tackling metastatic disease.
Creative Biolabs' VLP Development service, built on the robust and highly programmable CPMV, offers an advanced, commercially viable platform for targeted drug delivery and next-generation cancer immunotherapy. We combine structural biology expertise with translational validation, providing our clients with high-precision, scalable, and inherently active therapeutic assets. Contact our team for more information and to discuss your project.
Reference
-
Singh, Akansha, et al. "Immunomodulatory effects of intratumoral cowpea mosaic virus and calreticulin nanoparticles in canine tumors: early results." Frontiers in Immunology 16 (2025): 1566394. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1566394.
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
